Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Open Access
- 8 July 2020
- Vol. 70 (3), 555-566
- https://doi.org/10.1136/gutjnl-2020-320946
Abstract
Objective Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS. Design We conducted a Phase Ib, placebo-controlled, randomised clinical trial of two dose levels of naproxen sodium (440 and 220 mg) administered daily for 6 months to 80 participants with LS, and a co-clinical trial using a genetically engineered mouse model of LS and patient-derived organoids (PDOs). Results Overall, the total number of adverse events was not different across treatment arms with excellent tolerance of the intervention. The level of prostaglandin E2 in the colorectal mucosa was significantly decreased after treatment with naproxen when compared with placebo. Naproxen activated different resident immune cell types without any increase in lymphoid cellularity, and changed the expression patterns of the intestinal crypt towards epithelial differentiation and stem cell regulation. Naproxen demonstrated robust chemopreventive activity in a mouse co-clinical trial and gene expression profiles induced by naproxen in humans showed perfect discrimination of mice specimens with LS and PDOs treated with naproxen and control. Conclusions Naproxen is a promising strategy for immune interception in LS. We have discovered naproxen-induced gene expression profiles for their potential use as predictive biomarkers of drug activity. Trial registration number gov Identifier: NCT02052908Keywords
Funding Information
- National Cancer Institute (HHSN261201200034I, HHSN261201500039I, P30 CA016672, R01 CA219463)
- Feinberg Family Foundation
- Emerson Cancer Collective Foundation (ECCRF 192069)
This publication has 29 references indexed in Scilit:
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2012
- Regulation of Immune Responses by Prostaglandin E2The Journal of Immunology, 2012
- Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch SyndromeJAMA, 2011
- Molecular Genetics of Colorectal CancerAnnual Review Of Pathology-Mechanisms Of Disease, 2011
- Functional roles for noise in genetic circuitsNature, 2010
- An Msh2 Conditional Knockout Mouse for Studying Intestinal Cancer and Testing Anticancer AgentsGastroenterology, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Resolving lung injury: a new role for Tregs in controlling the innate immune responseJCI Insight, 2009
- Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch SyndromeThe New England Journal of Medicine, 2008
- Stochasticity in gene expression: from theories to phenotypesNature Reviews Genetics, 2005